Vanderbilt and Resolution Bioscience to present at AACR 2017 on longitudinal monitoring of cell-free DNA in patients with small cell lung cancer
SEATTLE, April 4, 2017 --Resolution Bioscience, Inc. is proud to announce the presentation by collaborators at Vanderbilt University School of Medicine and Northwestern University School of Medicine at today's AACR conference in Washington D.C.
Results: We detected somatic, disease-associated mutations in the cfDNA of 78% of patient samples (21/27). The allele frequency of cfDNA ranged from ≤0.5% to ≥85%. The most commonly mutated genes were TP53 and RB1, which were found in 17/27 and 10/27 samples, respectively. We also detected single nucleotide variants in PIK3CA (3/27) and PTEN (1/27) as well as copy number variants in MYC and MYCL1 (2/27). The observed mutant allele frequencies in longitudinal samples tracked closely with treatment responses. Strikingly, we found instances where the assay detected the reappearance of tumor-associated markers several weeks before clinical evidence of relapse was detected.
Conclusions: cfDNA sequencing allows for improved monitoring of disease burden, depth of responses to treatment, and timely warning of disease relapse in patients with SCLC.Read more
Resolution Bioscience Announces Collaboration on Liquid Biopsies with Frederick National Laboratory for Cancer Research
SEATTLE, September 7, 2016 /PRNewswire/ --Resolution Bioscience, Inc. today announced that it has entered into an agreement with the Leidos Biomedical Research Inc, which operates the Frederick National Laboratory for Cancer Research, to evaluate Resolution Bio's ctDx™ novel chemistry and proprietary bioinformatics data analysis pipeline. The agreement includes training of the Frederick National Laboratory's scientific staff, an effort that is already underway, as well as potential publication of results.Read more
SEATTLE, July 14, 2016 /PRNewswire/ -- Resolution Bioscience is pleased to announce its participation in the upcoming FDA-AACR Liquid Biopsies in Oncology Drug and Device Development Workshop on July 19th, 2016. The purpose of this workshop is to provide a forum for the discussion of relevant scientific advances in the field of liquid biopsies and of the regulatory environment that will support the translation of this emerging technology into improved patient care. The analysis of tumor-derived cell-free DNA (cfDNA) in plasma, a noninvasive method for detecting genetic alterations in tumors, holds considerable promise both for improving cancer diagnoses and monitoring and in drug development.Read more
Resolution Bioscience's ctDx Blood-based NGS Platform used for Plasma Genotyping and Longitudinal Monitoring of ALK Fusion Positive Patients in Clinical Trial
June 1, 2016 — Resolution Bioscience today announced that its Resolution ctDx™ blood-based NGS platform was used to detect ALK fusions, ALK resistance mutations and other driver mutations in patients' circulating tumor DNA in a phase I/II clinical trial of the ALK inhibitor X-396 (ensartinib), Xcovery's lead drug candidate in development for the treatment of ALK-positive non-small cell lung cancer (NSCLC). The results of this study will be presented at the 2016 ASCO meeting in Chicago and in a publication to follow.Read more
May 25, 2016 — Resolution Bioscience of Bellevue, WA announces an ongoing study involving the clinical application of DNA sequencing of circulating tumor DNA in the peripheral blood of lung cancer patients. The study is led by Dr. Keith Eaton, UW Associate Professor of Medicine, and UW Medicine oncologist at the Seattle Cancer Care Alliance.Read more
May 15, 2016 — Our ctDx platform was covered in GEN's coverage of the liquid biopsy industry.Read more
October 23, 2015 — Coverage of our cell-free DNA platform and publication in Clinical Cancer Research
Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer.
Seattle, Washington May 20, 2015 — Resolution Bioscience announced today the successful results from their CLIA validation of ctDx ALK™, a blood-based liquid biopsy for an ALK-gene fusion driver mutation found in non-small cell lung carcinoma (NSCLC), the most common form of this cancer. Researchers or clinicians can now use the test to guide patients to personalized therapies and direct them into clinical trials with a standard blood sample.
The Department of Health, the CLIA authority in Washington State, surveyed the laboratory and gave its highest assessment of “no deficiencies.”Read more
Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer
First clinically actionable, comprehensive liquid biopsy assay that can discover gene fusions that drive lung cancer.
Seattle, Washington (PRWEB) April 16, 2015 Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science and Resolution Bioscience, Inc. today announced the successful completion of a collaborative agreement to co-develop a novel, blood-based, clinic ready, Next Generation Sequencing (NGS) assay for non-small cell lung cancer (NSCLC). The collaboration is the first to demonstrate the successful sequencing of clinically actionable ALK, RET, and ROS1 fusions in blinded plasma samples and highlights the ability to discover all types of actionable mutations in a single assay from a standard blood draw. The results will be presented at the 2015 American Association for Cancer Research (AACR) meeting on April 19th and in a joint publication to follow.Read more